Apollomics Inc. (APLM)
(Delayed Data from NSDQ)
$0.16 USD
-0.01 (-3.66%)
Updated Oct 4, 2024 04:00 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Apollomics Inc. [APLM]
Reports for Purchase
Showing records 1 - 8 ( 8 total )
Company: Apollomics Inc.
Industry: Unclassified
Company: Apollomics Inc.
Industry: Unclassified
Uproleselan Misses Primary Endpoint in Phase 3; Lowering PT to $2
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Apollomics Inc.
Industry: Unclassified
Full Year 2023 Financials Reported; Lowering PT to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Apollomics Inc.
Industry: Unclassified
Vebreltinib Receives Conditional Approval in China; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Apollomics Inc.
Industry: Unclassified
Phase 2 KUNPENG Data For Vebreltinib Consistent With Earlier Study; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Apollomics Inc.
Industry: Unclassified
Significant Near-Term Data Catalysts; 1H23 Financials; Modulating PT to $17
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Apollomics Inc.
Industry: Unclassified
Competitive Landscape Updates From ASCO Conference; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Apollomics Inc.
Industry: Unclassified
A Burgeoning Pipeline Pursuing Validated Targets; Initiating at Buy and $18
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
|